Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Leuk Lymphoma. 2021 Sep;62(9):2141-2150. doi: 10.1080/10428194.2021.1901091. Epub 2021 Mar 21.
Although outcomes of transformed diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) were improved using rituximab-combined immunochemotherapy, the efficacy of subsequent rituximab maintenance (RM) remains unclear. We retrospectively analyzed the prognoses of 519 patients with DLBCL and 62 patients with concurrent DLBCL and FL (concurrent-DLBCL/FL). Progression-free survival (PFS) was shorter in patients with concurrent-DLBCL/FL than in DLBCL (=.030). Twenty-four patients with concurrent-DLBCL/FL received RM after induction therapy, and they achieved better OS and PFS (=.010 and <.001, respectively) with lower risk of relapse (<.001) than the non-RM group. Moreover, concurrent-DLBCL/FL showed better subsequent OS and PFS after recurrence than DLBCL (=.0083 and =.0044, respectively). Our study indicates that in the face of a high relapse rate, concurrent-DLBCL/FL is manageable and benefits from RM.
虽然利妥昔单抗联合免疫化疗改善了滤泡性淋巴瘤（FL）转化的弥漫性大 B 细胞淋巴瘤（DLBCL）的预后，但随后的利妥昔单抗维持（RM）的疗效仍不清楚。我们回顾性分析了 519 例 DLBCL 患者和 62 例同时患有 DLBCL 和 FL（并发-DLBCL/FL）患者的预后。并发-DLBCL/FL 患者的无进展生存期（PFS）短于 DLBCL（=.030）。24 例并发-DLBCL/FL 患者在诱导治疗后接受 RM，与非 RM 组相比，OS 和 PFS 更好（=.010 和<.001，分别），复发风险更低（<.001）。此外，并发-DLBCL/FL 在复发后具有更好的后续 OS 和 PFS ，优于 DLBCL（=.0083 和=.0044，分别）。我们的研究表明，在面对高复发率时，并发-DLBCL/FL 是可管理的，并受益于 RM。
